Avalon GloboCare Corp. and its unit Avactis Biosciences Inc. have entered into a joint venture and exclusive license agreement with Arbele Ltd. to co-develop certain cancer therapies.

Under the terms of the agreement, Freehold, N.J.-based Avalon will gain access to Arbele's transposon-based chimeric antigen receptor or CAR-T and CAR-Natural Killer, or NK, cellular therapies.

CAR-T cell therapy is a form of treatment that involves taking a person's own immune cells and modifying them to fight cancer cells when infused back into the body.

This joint venture will grant Avalon, a biotech developer and healthcare service provider, the opportunity to accelerate the clinical development of more effective and safer CAR-T/CAR-NK therapies, such as those developed by Arbele, based on Avalon's hospital network for cellular therapy and its bio-production facility in China, according to a Jan. 3 news release.

In October, Avactis formed a joint venture with Arbele to advance cancer immunotherapies in China.

Privately held Arbele is a biopharmaceutical company focusing on acceleration and expansion of immunotherapy technology and product development to treat advanced stages of cancers.